Sysmex Corporation · TSE:6869
Sysmex — H1 FY2007 Earnings Presentation
26 slides from Sysmex's earnings presentation, November 2007
Slide 1: Half Year 2007 Business Results
A Unique & Global Healthcare Testing Company Half Year 2007 Business Results Financial Highlights and Future Opportunities Hisashi Ietsugu President and CEO SYSMEX CORPORATION
Slide 2: Contents
Contents Outline of Half Year 2007 Results Future Opportunities FY2007 Consolidated Earnings Forecast Forward-looking Statements This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysmex Group). These forward-looking statements are based on
Slide 3: Outline of Half Year 2007 Results
Outline of Half Year 2007 Results •Topics •Financial Highlights •Breakdown of Net Sales and Ordinary Income •Breakdown of Balance Sheet •Consolidated Cash Flow •Geographic Segment Information A Unique & Global Healthcare Testing Company
Slide 4: Topics - 1
Outline of Half Year 2007 Results (ending in March 2008) Topics - 1 New products ¾ Marketing of the three products in the POCTEM S series of rapid diagnostic kits for respiratory infections 9 Subject infections: influenza, RS virus, adenovirus ¾ Marketing of multiparameter automated hematology analy
Slide 5: Topics - 2
Outline of Half Year 2007 Results (ending in March 2008) Topics - 2 Affiliates and offices ¾ Expansion of our sales and support network in Central Europe 9 Establishment of bases in Austria, Hungary, Czecho, and Slovakia ¾ Acquisition of a pharmaceutical production license at our plant in Wuxi, Chin
Slide 6: Financial Highlights
Outline of Half Year 2007 Results (ending in March 2008) Financial Highlights (Sales) (Income) Exchange rate in the preceding midterm report： 60 10 1US$=¥115.4, 1EUR=¥146.0 (in billions of JPY) Exchange rate in this midterm report： 52.9 1US$=¥119.3, 1EUR=¥162.3 50 47.4 (in billions of JPY) 8 As perc
Slide 7: Breakdown of Net Sales and Ordinary Income
Outline of Half Year 2007 Results (ending in March 2008) Breakdown of Net Sales and Ordinary Income ※FX impact excluded from regional sales below Gross margin increased as a result of a 0.3% improvement in cost ratio Increased SG&A up2.6 (in billions of JPY) (in billions of JPY) ＡＰ up0.13 China Euro
Slide 8: Breakdown of Balance Sheet
Outline of Half Year 2007 Results (ending in March 2008) Breakdown of Balance Sheet (in billions of JPY) Others Others Retained Intangible fixed 0.73 earnings 0.93 assets Fixed assets Net Assets 1.6 UP4.5 UP3.9 Tangible fixed assets 3.5 1.5 Current Liabilities Inventories assets 0.50 UP1.6 1.2 UP0.9
Slide 9: Consolidated Cash Flow
Outline of Half Year 2007 Results (ending in March 2008) Consolidated Cash Flow (in billions of JPY) 6 5.6 4.2 4.2 3 2.0 1.2 0.43 0 △ 0.31 △ 0.90 △0.63 △1.6 △3 △3.5 Increase/decr ease in “cash △ 5.1 △6 and cash Operating CF Investing CF Financing CF equivalents” 2006.3 H.Y. 2007.3 H.Y. 2008.3 H.Y. ※
Slide 10: Geographic Segment Information (Americas & Europe)
Outline of Half Year 2007 Results (ending in March 2008) Geographic Segment Information (Americas & Europe) (in billions of JPY) 【 Americas 】 (Net Sales to (Operating ¾ Favorable trend in sales to blood centers Outside customers) Americans Income) 12 1.5 ¾ Extensive orders from integrated health net
Slide 11: Geographic Segment Information (China & AP)
Outline of Half Year 2007 Results (ending in March 2008) Geographic Segment Information (China & AP) (in billions of JPY) 【China】 (Net Sales to (Operating Outside customers) China Income) ¾ Extensive orders for systems in the hematology segment 4 0.8 ¾ Cost pressure due to reduction of test expenses
Slide 12: Geographic Segment Information (Japan)
Outline of Half Year 2007 Results (ending in March 2008) Geographic Segment Information (Japan) 【Japan】 (in billions of JPY) Japan ¾ Cost pressures from medical institutions whose management (Operating <Including Korea (Sales ) faces harsh circumstances and Taiwan> Income) 35 6 ¾ Accelerated reorgan
Slide 13: Future Opportunities
Future Opportunities • Approaches in each geographical segment 9 Coverage of the US hospital market 9 Direct and indirect sales areas in Europe • Life science business development • Progress in R&D (Life Science) A Unique & Global Healthcare Testing Company
Slide 14: Americas - increased recognition in the market!
Future business development - approaches in each geographical segment Americas- increased recognition in the market! As percentage of (in billions of JPY) 2008.3 H.Y. the 2007.3 H.Y. (Net Sales to Americas (Operating Outside customers) Income) Sales １０．１ １１１．９％ ※Blue: Full Year 25 4.0 Red: Half Year
Slide 15: Coverage of the US hospital market
Future business development - approaches in each geographical segment Topics Coverage of the US hospital market 14% 18% ¾ Completion of the basic setup for sales in the US hospital market ¾ Sales and support setup 9 Improvement of support personnel capabilities for higher levels of customer satisfac
Slide 16: Europe - Full development of business driven by brands
Future business development - approaches in each geographical segment Europe- Full development of business driven by brands As percentage of (in billions of JPY) 2008.3 H.Y. the 2007.3 H.Y. Europe Sales １９．２ １３０．２％ (Net Sales to (Operating Outside customers) Income) ※Blue: Full Year Operating 40 10
Slide 17: Direct and indirect sales areas in Europe
Future business development - approaches in each geographical segment Topics Direct and indirect sales areas in Europe 【Direct sales areas】 ¾ Establishment of the subsidiary Sysmex Digitana in Switzerland 9 Transformation of a local distributor into a subsidiary ¾ Establishment of business bases in
Slide 18: China - Bolstering of activities as a total supplier
Future business development - approaches in each geographical segment China - Bolstering of activities as a total supplier As percentage of (in billions of JPY) 2008.3 H.Y. the 2008.3 H.Y. (Operating (Net Sales to Outside customers) China Income) Sales ３．９ １２２．２％ 9 ※Blue: Full Year 3 Red: Half Year
Slide 19: AP - higher levels of performance and improvement of the medical infrastructure
Future business development - approaches in each geographical segment AP - higher levels of performance and improvement of the medical infrastructure As percentage of (in billions of JPY) 2008.3 H.Y. ＜Excluding the ROK and Taiwan＞ the 2007.3 H.Y. (Net Sales to (Operating Outside customers) AP Income
Slide 20: Japan - buildup of business as a total supplier
Future business development - approaches in each geographical segment Japan - buildup of business as a total supplier (in billions of JPY) As percentage of (Sales ) Japan (Operating 2008.3 H.Y. Income) ＜Including the ROK and Taiwan＞ the 2007.3 H.Y. 80 <Including Korea 12 and Taiwan> Sales ３０．９ １０２．０
Slide 21: Life science business development
Future business development Life science business development ¾ System ¾ System for for rapid rapid detection detection of of lymph lymph node node metastasis metastasis Promotion of clinical utility through presentations and papers at learned societies 9 St. Gallen presentation, "Clinical Oncolog
Slide 22: Progress in R&D (Life Science)
Future business development Progress in R&D (Life Science) Research Clinical Study Application/ Launch NHI price Approval listing (Clinical Research) (Clinical trial) Cervical cancer screening technology Clinical Research underway NEW High sensitivity Cytological Technology NEW Cancer detection t
Slide 23: FY2007 Consolidated Earnings Forecast
FY2007 Consolidated Earnings Forecast • FY2007 Consolidated Earnings Forecast • Projected Dividend for FY2007 A Unique & Global Healthcare Testing Company
Slide 24: FY2007 Consolidated Earnings Forecast
FY2007 Consolidated Earnings Forecast FY2007 Consolidated Earnings Forecast FY2007 Consolidated Earnings Forecast ¾ Sales: ¥112 billion ¾ Ordinary Income: ¥15.3 billion ¾ Income:¥ 9.8 billion ¾ Ordinary Income ratio: ¥13.7% ¾ Income ratio:8.8% Investment plan ¾ Equipment: ¥8.3 billion ¾ R&D: 9.8 bil
Slide 25: Projected Dividend for FY2007
FY2007 Consolidated Earnings Forecast Projected Dividend for FY2007 Dividends Interim Year-end Total ratio dividend dividend (Consolidate) FY2007 ¥ ２０ ¥ ２０ ¥ ４０ ２０．８％ FY2006 ¥ １６ ¥ ２０ ¥ ３６ ２０．０％ 25
Slide 26: Challenging the Frontiers of Healthcare Testing
Challenging the Frontiers of Healthcare Testing SYSMEX CORPORATION <Contact> IR & Corporate Communication Div. Phone: 81-078-265-0500 Email: [email protected] URL: www.sysmex.co.jp END A Unique & Global Healthcare Testing Company